Shan Li

Shan Li is an accomplished researcher in the field of oncology and immunotherapy, currently serving as a Research Scientific Associate Director at Takeda since January 2022, focusing on the development of off-the-shelf allogeneic cell therapies. Prior to this role, Shan held positions at Poseida Therapeutics as a Scientist II, where co-led the first allogeneic dual CAR-T pipeline product, and at Eureka Therapeutics, where contributions included the development and optimization of the ARTIMESTM-T cell platform. Experience also includes working at AbbVie on novel target discovery and validation in drug development, and conducting postdoctoral research at Rush University Medical Center that identified critical regulators of the NF-kB signaling pathway. Education includes a Ph.D. from Tsinghua University, specializing in Oncology and Cancer Biology.